

17. Mitteilungsblatt

Nr. 22

Mitteilungsblatt der Medizinischen Universität Wien
Studienjahr 2025/2026
17. Stück; Nr. 22

Bevollmächtigungen

22. Bevollmächtigungen gem. § 27 Abs. 2 UG

22. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitel	Organisationseinheit	Projektleiter(in)
FA731V0201	AAA Biomarker	Allgemeinchirurgie_731	Brostjan Christine
FA731W0101	Single-Cell Transcriptomic Analysis of Immune Modulation by Extracorporeal Photopheresis in Lung Transplant Recipients	Allgemeinchirurgie_731	Weijler Anna
FA731X0402	Influence of Intermittent Normobaric Hypoxia in Altitude Preconditioning on HIF-1. regulated Markers	Allgemeinchirurgie_731	Mühlbacher Jakob
FA731X0501	Prospective evaluation of the results of pancreatic left resections using disposable endoscopic cutting stapler from Panther Healthcare.	Allgemeinchirurgie_731	Klaiber Ulla
FA731X0601	Rational and Personalized Targeting of Chemotherapy Resistance in Gastrointestinal Cancer	Allgemeinchirurgie_731	Längle Johannes
FW731X0101	Folate and metabolic-associated liver fibrosis (FAMIS)	Allgemeinchirurgie_731	Mölzer Christine
FA738A3202	Verbesserung des Muskelstoffwechsels durch eine Kombination aus Muskelaktivierung und erhöhter Eiweißzufuhr: eine randomisierte, Ergebnisbeurteilter-verblindete Studie zum Wirksamkeitsnachweis (IMEMPRO)	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Schaller Stefan
FA738A3203	Postoperative Metabolomics Pilotstudie zur auf Intensivstation erworbener Muskelschwäche (MIRACLE-I Studie)	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Schaller Stefan
FA738A3301	Cp50 von Remimazolam	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Müller Johannes

FA738C1201	Development of an artificial intelligence for mechanical ventilation optimization during one-lung ventilation	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Wendel Garcia Pedro
FA613A0505	EUROpean Epitranscriptomics of Cancer Academy	Anatomie und Zellbiologie_310	Jantsch Franz-Michael
FA746A0322	Abbildungsqualität von EDoF IOLs (Through Focus Response and Through Focus MTF von EDoF IOLs im klinisch relevanten Defokusbereich)	Augenheilkunde und Optometrie_746	Pieh Stefan
FA746A0805	General Research Funding	Augenheilkunde und Optometrie_746	Abela-Formanek Claudette
FA746A0806	Data Transfer Agreement: Evaluation of the Visual Outcome of a Multifocal Intraocular Lens (Amendment)	Augenheilkunde und Optometrie_746	Abela-Formanek Claudette
FA746A1662	Deciphering AMD by deep phenotyping and machine learning- Prospective Study - PINNACLE (Part 1) & SUMMIT (Part 2)	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1663	Annotation License Agreement	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1664	Durchschnittliche Dosierungsintervalle von HighDose anti-VEGF Substanzen bei nAMD in real-life	Augenheilkunde und Optometrie_746	Sacu Stefan
FA746A2506	Intra- and extramural exchange of optical coherence tomography images for treatment decisions in Austria based on Tele-Ophthalmological Monitoring (AUTO-MO)	Augenheilkunde und Optometrie_746	Gerendas Bianca
FA746A2615	A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A2903	"A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)"	Augenheilkunde und Optometrie_746	Kriechbaum Katharina Franziska

FA746A4301	A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)	Augenheilkunde und Optometrie_746	Weigert Günther
FA746A4401	"A Phase 3, Open-Label, Multicenter, Randomized Study to evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta"	Augenheilkunde und Optometrie_746	Rezar-Dreindl Sandra Margaretha
FA662A0802	Innovationscheck CL Chirurgie Training	Biomedizinische Forschung und Translationale Chirurgie_308	Schneider Karl
FA662A0902	Therapeutic Evaluation of Vamorolone in Cardiac and Fibrotic Pathologies of Duchenne Muscular Dystrophy	Biomedizinische Forschung und Translationale Chirurgie_308	Kiss Attila
FA662A1006	PathBreaker- Gezielte Hemmung fibrotischer Signalwege	Biomedizinische Forschung und Translationale Chirurgie_308	Hohensinner Philipp
FA662A1202	Preclinical non-GLP in-vivo safety pilot study for a porcine based BioCover	Biomedizinische Forschung und Translationale Chirurgie_308	Bammer Manfred
FA662A1301	Temporäre selbst-resorbierbare und selbst-haltende epikardiale Schrittmacherdrähte mit Mechanismus zum Abwurf der Spitze für die postoperative Stimulation nach herzchirurgischen Eingriffen	Biomedizinische Forschung und Translationale Chirurgie_308	Santer David
FA696A0202	MultiOmics for Optimizing Novel biomarker Signatures in High-throughput for Omics-based Translational precision medicine	Core Facilities_2012	Kratochwill Klaus
FA722A0208	HPV Datenanalyse aus einer Datensammlung zu HPV Subtypen	Dermatologie_722	Stary Georg
FA722A2601	SarcoID	Dermatologie_722	Kopf Aglaja

FA722A2701	Automating knowledge extraction from large dermatopathological datasets to establish objective and interpretable diagnostic frameworks	Dermatologie_722	Tschandl Philipp
FA722B1147	A phase 2 and phase 3 peri-operative trial of Fianlimab and Cemiplimab compared with anti-PD1 alone in patients with resectable stage III and IV Melnaoma.	Dermatologie_722	Höller Christoph
FW722A0402	The Pathogenesis of Indolent Cutaneous B Cell Lymphoma	Dermatologie_722	Griss Johannes Maximilian
FW722A0701	NextGen InVitro Evolution: Entschlüsselung des Phagengenoms	Dermatologie_722	Wielscher Matthias
FW722A0801	Decipher Syphilis: Skin Immunity Against Treponema pallidum	Dermatologie_722	Eder Julia
FA751C0687	A non-interventional study for Kisqali (ribociclib) in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence to evaluate real-world effectiveness, safety profile, patient compliance and quality of life	Frauenheilkunde_751	Singer Christian
FA751C1212	Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer	Frauenheilkunde_751	Pfeiler Georg
FA751C1903	Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation and clinical management	Frauenheilkunde_751	Tan Yen Yen
FA751C2604	A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer	Frauenheilkunde_751	Concin Nicole

FA751C2605	An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer	Frauenheilkunde_751	Concin Nicole
FA751C2606	FOLRalpha Heterogeneity in Epithelial Ovarian Cancer - A Translational Pilot Study	Frauenheilkunde_751	Concin Nicole
FA751C2607	A Phase 2, Study Evaluating the Efficacy and Safety of TORL-1-23 In Women in Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6	Frauenheilkunde_751	Concin Nicole
FA751D1207	Comparison of saliva and serum as test media before and after the application of transdermal bioidentical progesterone hormone therapy in postmenopausal women	Frauenheilkunde_751	Ott Johannes
FA657A0103	Die bronzzeitliche Bevölkerung von Syrakus (Sizilien)	Gerichtsmedizin_304	Kanz Fabian
FA744B0805	Audiometrien für ARTEMIDE Gastric 01	Hals-, Nasen- und Ohrenkrankheiten_744	Riss Dominik
FW744C0101	Voice conversion for the processing of pathological speech	Hals-, Nasen- und Ohrenkrankheiten_744	Aichinger Philipp
FA732A0203	EOS - Aortic Stapler Device	Herz- und Thorakale Aorten Chirurgie_732	Osorio Emilio
FA732A0204	Acute Animal Model MAZE	Herz- und Thorakale Aorten Chirurgie_732	Osorio Emilio
FA732A0512	3D-Printed Blood Pump for Pediatric Patients	Herz- und Thorakale Aorten Chirurgie_732	Granegger Marcus
FA732A0604	EACTS INNOVATION GRANT PROGRAMME	Herz- und Thorakale Aorten Chirurgie_732	Zimpfer Daniel
FA732A0806	Surgical Measurement for Accurate Revascularization using Transit-time FLOW (SMARTFLOW): Patency	Herz- und Thorakale Aorten Chirurgie_732	Sandner Sigrid
FA732A1002	Initiale Sicherheit und Leistung der CellFX nsPFA Technologie zur	Herz- und Thorakale Aorten Chirurgie_732	Ehrlich Marek

	chirurgischen Behandlung von Vorhofflimmern		
FA732A1301	Registerstudie mit dem Elektrodenlosen Herzschrittmacher AVEIR in Europa und dem mittleren Osten	Herz- und Thorakale Aortenchirurgie_732	Khazen Cesar
UE73206004	CDG Internship 2025	Herz- und Thorakale Aortenchirurgie_732	Granegger Marcus
FA684A0106	Impaired Microglial Phagocytosis: A Potential Link to Ether Phospholipids and Synaptic Pruning	Hirnforschung_360	Berger Johannes
FA684A0302	Deciphering astrocyte-driven neurotoxicity in X-ALD: towards targeted neuroprotection using HDAC3 inhibition	Hirnforschung_360	Weinhofer-Molisch Isabelle
FW620A0101	Prefrontal Cellular and Circuit Dynamics of Decision Making	Hirnforschung_360	Klausberger Thomas
UE60106001	LBI SOAP Beistellungen mit Refundierung	Ignaz Semmelweis Institut (ISI) - Interuniversitäres Instit_400	Krammer Florian
CD10271102	Christian Doppler Laboratory for Innovative Allergy Therapeutics	Innere Medizin I_711	Starkl Philipp
FA711A0318	A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)	Innere Medizin I_711	Burgmann Heinz
FA711A0319	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease	Innere Medizin I_711	Burgmann Heinz
FA711A0320	A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis	Innere Medizin I_711	Burgmann Heinz
FA711A0321	CAR-T Register	Innere Medizin I_711	Burgmann Heinz

FA711A0322	CA061-1011: A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)	Innere Medizin I_711	Burgmann Heinz
FA711B1063	Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study	Innere Medizin I_711	Preusser Matthias
FA711B1064	Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patientes Presenting with Newly diagnosed or Progressing Brain Metastases (The TUXEDO-4 Study)	Innere Medizin I_711	Preusser Matthias
FA711B1065	A Phase 3, Open-Label, Multicenter, Randomized Study of a Combination of CBP501, Cisplatin and Nivolumab or Physician's Choice of Therapy for over the 3rd or 3rd Line Treatment of Patients with Advanced Pancreatic Adenocarcinoma [FUJI-PanCo1]	Innere Medizin I_711	Preusser Matthias
FA711B1066	IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicion's Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triplenegative Brest Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment	Innere Medizin I_711	Preusser Matthias
FA711B1067	Neoepitope profiling of glioblastoma	Innere Medizin I_711	Preusser Matthias
FA711B1068	External Control Arm Study to Support HTA Submissions for T-DXd for Patients with HER2 IHC3+ Solid tumors (D967VR00001)	Innere Medizin I_711	Preusser Matthias

FA711B1069	DESTINY-Biliary Tract Cancer-01: Eine Phase-3-Studie zu Trastuzumab Deruxtecan (T-DXd) und Rilvegostomig versus dem Versorgungsstandard Gemcitabin, Cisplatin und Durvalumab zur Erstlinientherapie bei lokal fortgeschrittenem oder metastasiertem HER2-exprimierendem Gallengangkrebs (D781PC00001)	Innere Medizin I_711	Preusser Matthias
FA711B1070	A randomized phase II Study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling (The PONTIAC Study)	Innere Medizin I_711	Preusser Matthias
FA711B1071	A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma	Innere Medizin I_711	Preusser Matthias
FA711B1072	A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2-positive Gastric Cancer	Innere Medizin I_711	Preusser Matthias
FA711B1073	PROCEADE PanTumor: A Phase Ib/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precentabart Tocentecan (M9140) in Participants With Advanced Solid Tumors (Master Protocol)	Innere Medizin I_711	Preusser Matthias
FA711B1074	A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma	Innere Medizin I_711	Preusser Matthias

FA711B1075	A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line-Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Innere Medizin I_711	Preusser Matthias
FA711B1076	AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond	Innere Medizin I_711	Preusser Matthias
FA711B1077	A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	Innere Medizin I_711	Preusser Matthias
FA711B1078	An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer	Innere Medizin I_711	Preusser Matthias
FA711C0967	Randomisierte, doppelblinde, placebokontrollierte Phase-3-Prüfung zu Bleximenib, Venetoclax und Azacitidin zur Behandlung von Patienten mit neu diagnostizierter akuter myeloischer Leukämie mit KMT2A-Rearrangements oder NPM1-Mutationen, die für eine invasive Chemotherapie nicht geeignet sind	Innere Medizin I_711	Valent Peter
FA711C0968	Eine doppelblinde, randomisierte, placebokontrollierte Phase-III-Studie zu Quizartinib, verabreicht in Kombination mit Induktions- und Konsolidierungstherapie und als Erhaltungstherapie bei erwachsenen Patienten mit neu diagnostizierter akuter myeloischer Leukämie, die FLT3-ITD-negativ ist (QuANTUM-Wild)	Innere Medizin I_711	Valent Peter

FA711Co969	A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Innere Medizin I_711	Valent Peter
FA711Co970	EpcorReal: A multi-country, prospective observational study of epcoritamab in NHL comprising two patient cohorts (3L+ [D]LBCL and 3L+ FL)	Innere Medizin I_711	Valent Peter
FA711Co971	Phase III randomized, open-label, international, multicenter, study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma	Innere Medizin I_711	Valent Peter
FA711Co972	A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) veneto-clax/obinutuzumab vs. fixed-duration (15 cycles) venetoclax/pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes	Innere Medizin I_711	Valent Peter
FA711C1423	CSL Behring Prof Heimburger Award 2025 Dr. Tim Dreier: Inherited impairment of endothelial cell function as an underlying mechanism in bleeding disorder of unknown cause	Innere Medizin I_711	Ay Cihan
FA711C1424	Pfizer Grant 96373381: Investigation of a functional TFPI assay for the on-site monitoring of anti-TFPI therapies in hemophilia	Innere Medizin I_711	Ay Cihan
FA711C1425	EHA Ukraine Bridge Support for Dr. Olha Svystak, PhD	Innere Medizin I_711	Ay Cihan

FA711C1426	NN7442-8454 Voyager2: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Peroral Doses of Inno8 in People with Haemophilia A	Innere Medizin I_711	Ay Cihan
FA711C1427	Sobi Forschungsförderung 2025-2027: Assessment of Comorbidities and Cardiovascular Health in People with Hemophilia	Innere Medizin I_711	Ay Cihan
FA711Do321	An interventional Phase 3, open-label, 2-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by <i>Aspergillus</i> spp., <i>Fusarium</i> spp., <i>Lomentospora prolificans</i> , <i>Mucorales</i> fungi, <i>Scedosporium</i> spp., or other multidrug resistant molds	Innere Medizin I_711	Burgmann Heinz
FA711Do322	Efficacy and safety of pyronaridine/artesunate in cystic echinococcosis: A pilot study Building new treatment options through clinical research for a neglected disease with limited treatment options	Innere Medizin I_711	Burgmann Heinz
FA711Do323	Early, non-invasive diagnosis of lung cancer by testing for viral biomarkers in exhaled breath air	Innere Medizin I_711	Burgmann Heinz
FW711Bo101	PLK1 in OSCC: Biologie und innovative therapeutische Ansätze	Innere Medizin I_711	Preusser Matthias
FA714B2718	A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126)	Innere Medizin II_714	Bergler-Klein Jutta
FA714B3114	Eine offene Verlängerungsstudie zur Beurteilung der Sicherheit und Wirksamkeit von Vutrisiran bei Patienten mit Transthyretin-Amyloidose mit Kardiomyopathie (ATTR-Amyloidose mit Kardiomyopathie)	Innere Medizin II_714	Kastner Johannes
FA714B3115	TRITON: Eine globale, randomisierte, doppel-blind. placebokontrollierte Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von Nucleosiran bei Patienten mit Transthyretin-vermittelter Amyloidose mit Kardiomyopathie	Innere Medizin II_714	Kastner Johannes

	(ATTR-Amyloidose mit Kardiomyopathie)		
FA714B4307	Eine randomisierte, doppelblinde, placebokontrollierte, klinische Prüfung der Phase III zur Bewertung der Auswirkungen von Maridebart Cafraglutid auf kardiovaskuläre Ergebnisse bei Teilnehmern mit atherosklerotischen kardiovaskulären Erkrankungen und Übergewicht oder Fettleibigkeit (MARITIME-CV).	Innere Medizin II_714	Krychtiuk Konstantin
FA714B4308	Wirksamkeit und Sicherheit von Bempedoinsäure in Kombination mit Ezetimib und entweder Rosuvastatin oder Atorvastatin bei Patienten mit primärer Hypercholesterinämie oder gemischter Dyslipidämie: eine Beobachtungsstudie	Innere Medizin II_714	Krychtiuk Konstantin
FA714B4707	Beobachtungsstudie zur Gewinnung von Erkenntnissen über die hypertrophe Kardiomyopathie und zur Erfassung von Beobachtungsergebnissen in der Praxis (DISCOVER-HCM): Europäische prospektive regionale Registerstudie.	Innere Medizin II_714	Badr Eslam Roza
FA714B4918	Atrial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) with HER2-activating mutations.	Innere Medizin II_714	Gangl Clemens
FA714B4919	ActFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer	Innere Medizin II_714	Gangl Clemens

FA714B4920	A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation	Innere Medizin II_714	Gangl Clemens
FA714B5503	NON-INTERVENTIONAL STUDY AGREEMENT Protocol CODE No. FollowMe (AT1001-030)	Innere Medizin II_714	Gatterer Constantin
FA714B5702	Aortic Stenosis Today: Modern Treatment options 2025 ESC Guidelines adoption, THV-E25-271	Innere Medizin II_714	Bartko Philipp Emanuel
FA714B5804	Advanced isotope-labelled protein standards for robust and scalable cardiovascular risk profiling	Innere Medizin II_714	Mayr Manuel
FA714B6107	ZEPHYR	Innere Medizin II_714	Hemetsberger Rayyan
FA714B6301	Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity	Innere Medizin II_714	Zelniker Thomas
FA714C0318	Effectiveness and Safety of Bempedoic Acid in combination with Ezetimibe and either Rosuvastatin or Atorvastatin in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study	Innere Medizin II_714	Schernthaner Gerit
FA714C1201	Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease - ELITE-BTK Trial	Innere Medizin II_714	Steiner Sabine
FA714D0805	A European multi-centre prospective cohort study in patients hospitalized for an acute exacerbation of COPD (CATALINA Study)	Innere Medizin II_714	Gompelmann Daniela
FW714D0101	Significance of P2RY2 in NSCLC - Bedeutung von P2RY2 bei NSCLC	Innere Medizin II_714	El-Gazzar Ahmed
UE71406022	Drug coated balloons in small and large vessel disease	Innere Medizin II_714	Koller Lorenz

UE71406024	Ausbildungsprogramm Elektrophysiologie	Innere Medizin II_714	Stojkovic Stefan
UE71406025	Kooperation MedUni Wien - ÖISM	Innere Medizin II_714	Hengstenberg Christian
FA714B2306	BIO RISK EVENT Trial	Innere Medizin II_714	Siller-Matula Jolanta
FA716B0630	A Phase 3 Randomized, Double- blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV).	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B0631	Effectiveness and Safety of Bempedoic Acid in combination with Ezetimibe and either Rosuvastatin or Atorvastatin in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study (TRICONOS).	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B1003	Mitochondrial Modifiers in Obesity	Innere Medizin III_716	Kiefer Florian
FA716B1406	Eine randomisierte, dreiarmige Studie der Phase III (doppelblind Debio 4126, placebokontrolliert und offen Debio 4126) zur Beurteilung der Wirksamkeit und Sicherheit von Debio 4126, einer 12-wöchigen Oktreotid- Formulierung bei Patienten mit Akromegalie, die zuvor mit Somatostatin-Analogen behandelt wurden.	Innere Medizin III_716	Vila Greisa
FA716C0918	A Double-Blind, Placebo- Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE)	Innere Medizin III_716	Böhmig Georg
FA716C0919	An Open- Label Phase IIa Trial Exploring the Safety, Tolerability and Efficacy of the T Cell Engager	Innere Medizin III_716	Böhmig Georg

	OM336 for Desensitization of Kidney Transplant Candidates		
FA716C1028	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation	Innere Medizin III_716	Oberbauer Rainer
FA716C1029	CA061-1011: A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)	Innere Medizin III_716	Oberbauer Rainer
FA716D0246	Expert consensus statement on the use of autoantibody testing in rheumatoid arthritis	Innere Medizin III_716	Smolen Josef
FA716D1103	A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis	Innere Medizin III_716	Kiener Hans
FA716D1704	A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjogren's Disease (SjD), (DAFFODIL)	Innere Medizin III_716	Studenic Paul
FA716D1705	A Phase 2 Multicenter Open-Label Study Of CC-97540 (BMS-986353) CD19-Targeted NEX-T CAR T Cells in Participants with Active SLE (Including Lupus Nephritis) with	Innere Medizin III_716	Studenic Paul

	Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants		
FA716D2503	Tracing the Path of Progressive Pulmonary Fibrosis (PPF): A Study on Prevalence, Risk, Progression, and Treatment Outcomes of PPF in Vienna	Innere Medizin III_716	Lechner-Radner Helga
FA716D2504	REAL-WORLD IMPACT OF BIMEKIZUMAB ON DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS PATIENTS INCLUDING THE EARLY SUBPOPULATION (EXPEDITE)	Innere Medizin III_716	Lechner-Radner Helga
FA716E1079	MUW-HCC machine-learning derived risk stratification-project	Innere Medizin III_716	Balcar Lorenz
FA716E1080	A Phase 2, multinational, multicenter, randomized, double-blind, placebocontrolled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderateto-severe ulcerative colitis	Innere Medizin III_716	Reinisch Walter
FA716E1081	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis	Innere Medizin III_716	Trauner Michael
FA716E1082	Clinical Benefit of Bulevirtide Therapy in Adult Patients With Chronic Hepatitis Delta Compared to a Historical Control Group Receiving Standard of Care	Innere Medizin III_716	Trauner Michael
FA716E1083	PROCEADE PanTumor A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)	Innere Medizin III_716	Trauner Michael
FA716E1201	A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV	Innere Medizin III_716	Reiberger Thomas

	Infection Not Virologically Suppressed with Bulevirtide (ECLIPSE 2)		
FA716C0831	An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis	Innere Medizin III_716	Schmidt Alice
FA730A0101	Developing Ewing Sarcoma Immunotherapy In Biomimetic Models	Kinder- und Jugendchirurgie_730	Radic Sarikas Branka
CD10278102	CD-Labor für Metaflammation in der Peritonealdialyse	Kinder- und Jugendheilkunde_781	Herzog Rebecca
FA781B2504	IMprove Psychosocial cAre and soCial supporT for children/adolescents with cancer and their families to improve quality of life for all	Kinder- und Jugendheilkunde_781	Leiss Ulrike
FA781B2505	European Youth Cancer Network	Kinder- und Jugendheilkunde_781	Leiss Ulrike
FA781B2711	Safety and Effectiveness of Safe Variable-depth bone Access Needle Study	Kinder- und Jugendheilkunde_781	Wagner Michael
FA781B3210	Advanced Resistance Mapping and Overcoming Relapse of ETMR (ARMOR)	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3211	Durchführung von Medizinischer Aus- und Weiterbildung in Form von Observerships	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3212	The ITTC Brain Translational Accelerator Platform	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3302	Beating the Odds: Standardized Hemodynamic Screening and Adjunctive Music Therapy for Brain Protection in the Preterm Infant	Kinder- und Jugendheilkunde_781	Göral Katharina
FA781D0801	A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years	Kinder- und Jugendheilkunde_781	Hanslik Andreas

	of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD)		
FA781D0802	A single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients, from birth to 18 years of age, with left ventricular systolic dysfunction (LVSD)	Kinder- und Jugendheilkunde_781	Hanslik Andreas
FA781F1017	Identifying and exploiting SLC39A14 regulatory mechanisms for the future development of therapeutics	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F1207	CARE-BONE CEE Project	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781F1208	A Phase 3, Open-Label, Multicenter, Randomized Study to evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781G0802	Fear of disease progression in pediatric kidney transplant recipients	Kinder- und Jugendheilkunde_781	Eibensteiner Fabian
UE78106027	Personalkosten Muskelforschung	Kinder- und Jugendheilkunde_781	Seidl Rainer
UE78106032	Psychosoziale Versorgung in der pädiatrischen Onkologie	Kinder- und Jugendheilkunde_781	Leiss Ulrike
FA765A0806	Ein kleines Imperium im medizinischen Bereich. Das Brünnlbad und die Fango-Heilanstalt in der NS-Zeit	Kinder- und Jugendpsychiatrie_765	Plener Paul
FA765A1201	BEAR Intervention	Kinder- und Jugendpsychiatrie_765	Schwarzenberg Julia
FA765A1301	Unterstützung für Geschwister von Jugendlichen mit einer Essstörung (Supporting siblings of adolescents with eating disorders)	Kinder- und Jugendpsychiatrie_765	Klang Julia
FW765A0101	MENTAL HEALTH LITERACY PARTY	Kinder- und Jugendpsychiatrie_765	Konicar Lilian

UE76506006	Stressmanagement und autonome Dysregulation bei Autismus-Spektrum-Störung	Kinder- und Jugendpsychiatrie_765	Kothgassner Oswald
FA729A1059	A single center, open-label, 3-period fixed-sequence, Phase I clinical Study to Evaluate the effect of BV100 on the Pharmacokinetics of Polymyxin B in healthy volunteers	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1060	BE READY NOW - EUROPEAN PARTNERSHIP FOR PANDEMIC PREPAREDNESS	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1061	A phase I, double-blind, randomized, SAD and MAD trial to evaluate the dose relationship of clinical safety, tolerability and pharmacokinetic parameters of AUR-001 (Ausodual®) administered via inhalation in healthy volunteers	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1062	Support MedUni's research activities	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1313	Non-interventional study to evaluate the anti-inflammatory effects and the clinical efficacy of topical water free cyclosporin 0.1% eye drops in patients with dry eye disease and associated ocular surface inflammation non-responding to artificial tears	Klinische Pharmakologie_729	Schmidl-Schordje Doreen
FA729A2002	Pharmacokinetics and Target Attainment of Aztreonam-Avibactam in Critically Ill Patients with Sepsis Receiving ECMO Support: A Prospective PK Study with Microdialysis	Klinische Pharmakologie_729	Jorda Anselm
FA729A2502	Effects of purified clinoptilolite-tuff, a procoagulant mineral, on ex vivo blood coagulation of healthy volunteers	Klinische Pharmakologie_729	Bischof Thorsten
FA729A2701	Impact of Continuous Glucose Monitoring (CGM) and Patient Education on Patients with Prediabetes identified with Point-of-Care tests in community pharmacies	Klinische Pharmakologie_729	Weiss-Tessbach Matthias

UE72906001	Erforschung von Arzneimitteltherapien bei Augenerkrankungen (Kooperation VIROS / Dr. Kampfer)	Klinische Pharmakologie_729	Garhöfer Gerhard
FA712A0513	Left versus Right metastatic Colon Cancer and Response to Treatment with EGFR or KRAS Modulator alone or in combination	Krebsforschung_712	Sibilia Maria
FA712A0916	ABCSG TR Ataraxis: Validation of a Prognostic and Predictive Foundation Model-Based AI Test in Breast Cancer: Analysis of ABCSG Clinical Trial Data for Enhanced Risk Stratification and Predicting Extended Endocrine Therapy Benefit	Krebsforschung_712	Filipits Martin
FA712A1207	Canine Extrachromosomal DNA (ecDNA) as a Comparable and Innovative Human Model for Cancer Detection and Therapy	Krebsforschung_712	Holzmann Klaus
FW712A0801	Manipulating drivers of transcriptional heterogeneity	Krebsforschung_712	Barozzi Iros
FW712A0802	OPTIMIZE: multiomics signature guiding neoadjuvant treatment	Krebsforschung_712	Barozzi Iros
FW712A0901	BEC specific activities of EGFR in liver disease	Krebsforschung_712	D'Artista Luana
FA793A2103	Checkit!	Labormedizin_793	Luf Anton
FA793B0125	Improved diagnosis of infection by accelerated pathogen detection in patients with sepsis and suspected blood stream infection	Labormedizin_793	Willinger Birgit
FA793B0126	Brilliance Candida 2 Agar/Spectra Candida Agar and Chromogenic C. Albicans Agar Clinical Performance Evaluation	Labormedizin_793	Willinger Birgit
FA793B0312	Performance evaluation of Cube Dx Pathogens xC product range for testing bacteria and fungi directly from ETDA blood / sterile body fluids and tissue.	Labormedizin_793	Makristathis Athanasios
FW793A0202	RNA Impfstoffe in Atherosklerose und Herzerkrankungen	Labormedizin_793	Binder Christoph
FW793A0501	Oligonucleotide mimotope profile mirrors antibody repertoire	Labormedizin_793	Afonyushkin Taras

FW793A0601	Dissecting neuronal responses caused by demyelination	Labormedizin_793	Licht-Mayer Simon
FA616A0405	The Nuclear Pore Complex: Bridging Membrane Remodelling and Lipid Metabolism	Max Perutz Labs_305	Köhler Alwin
FA616A0802	Exploring the Prevalence and Structural Analysis of Outer Membrane Proteins in Brucella Detected in Humans, Cattle, Cattle Products and Environment	Max Perutz Labs_305	Dong Gang
FW616A0101	Posttranscriptional mechanisms for maintaining homeostasis	Max Perutz Labs_305	Karagöz Gülsün Elif
FW616A0201	Flagellar pocket membrane-Cytoskeleton dynamics in T. brucei	Max Perutz Labs_305	Dong Gang
FW618A0103	tRNA ligase complex as a target of a new degradation pathway	Max Perutz Labs_305	Martinez Javier Augusto
FW618A0201	Significance of RNA Processing Bodies in Parkinson's Disease	Max Perutz Labs_305	Hallacli Erinc
FA602A0125	Unifying Framework for Patient-centred Clinical-study Endpoints derived from Digital Health Technologies	Medical Data Science_303	Stamm Tanja
FA631A0403	Accelerate Europe	Medical Data Science_303	Samwald Matthias
FA631A0702	Orthodontic Platform Proof of Concept	Medical Data Science_303	Bogunovic Hrvoje
FA632A0310	Characterisation of complex clinical trials in the European regulatory context	Medical Data Science_303	König Franz
FA632A0509	Use of causal inference methods commonly used in non-interventional studies to estimate treatment effects in clinical trials	Medical Data Science_303	Ristl Robin
FA632A0701	Statistical Analyses for the effect of pre-operative intravenous crystalloids on post-induction blood pressure - Kooperation KLI 1097	Medical Data Science_303	Graf Alexandra
FA660A0710	Adjunct-PI LBI Network Medicine	Medical Data Science_303	Thurner Stefan
UE60206003	Ludwig Boltzmann Institut Outcomes	Medical Data Science_303	Stamm Tanja
UE63106002	EMBO ALTF 699-2025	Medical Data Science_303	Kiraly Balint

FA605A3804	Integrated Pump-Patient Interaction Analysis and Hemodynamic Decision Support Based on Corheart 6 Left Ventricular Assist Device Data	Medizinische Physik und Biomedizinische Technik_340	Schlöglhofer Thomas
FA605A4102	A fully wearable electro-stimulating system designed to improve mobility and foot health in diabetic peripheral neuropathy patients	Medizinische Physik und Biomedizinische Technik_340	Raspopovic Stanisa
FA605A4201	Magnetic Resonance Spectroscopy (MRS) Study	Medizinische Physik und Biomedizinische Technik_340	Juchem Christoph
FW605A0401	Retinal Staging via Bayesian Reverse Modeling of pRF Data	Medizinische Physik und Biomedizinische Technik_340	Linhardt David
FA736A0705	Precisis GmbH, EASEE4YOU - Klinische Prüfung der Sicherheit und Wirksamkeit der transkraniellen Kortextstimulation mit dem EASEE System zur Behandlung medikamentenrefraktärer fokaler Epilepsie bei jugendlichen Patienten im Alter von 12 bis 17 Jahren	Neurochirurgie_736	Rössler Karl
FW736A0201	GLIO-COMBO Targeting tumor heterogeneity in pediatric high-grade glioma	Neurochirurgie_736	Lötsch-Gojo Daniela
FA761A1184	Agreement on the Conduct of a Clinical Study Pursuant to the Austrian Medical Devices Act/MDR	Neurologie_761	Berger Thomas
FA761A1185	A phase 3, randomized, double-blinded, double-dummy study evaluating the efficacy and safety of Empasiprubarb versus Intravenous Immunoglobulin in adults with Multifocal Motor Neuropathy	Neurologie_761	Berger Thomas
FA761A1186	Characterising Clinical, Radiological, and Biological Profiles in MOGAD/MS Overlap Syndrome: a Multicentre Observational Study	Neurologie_761	Berger Thomas

FA761A1187	A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)	Neurologie_761	Berger Thomas
FA761A1188	A Phase 2a, Multi-Center, Randomized, Parallel Group, Double-Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability as well as Explorative Efficacy of the Orthosteric Selective Muscarinic M1 Agonist NSC001 in Mild to Moderate Alzheimer's Disease	Neurologie_761	Berger Thomas
FA761A1189	An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds	Neurologie_761	Berger Thomas
FA761A1190	Epidemiology of myasthenia gravis in Austria	Neurologie_761	Berger Thomas
FA761A1191	A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Neurologie_761	Berger Thomas
FA761A1192	A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubarb Versus Intravenous Immunglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy	Neurologie_761	Berger Thomas
FA761A1193	Non-interventional, prospective, multicenter study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi for relapsing forms of	Neurologie_761	Berger Thomas

	multiple sclerosis (RMS) with active disease in daily clinical practice		
FA761A1301	Towards EPileptomics - a CONNectome-based perspective on epileptic networks, cognition and clinical outcome	Neurologie_761	Bonelli-Nauer Silvia
FA796A0902	Anti-IgLON5 disease: From Neuroinflammation to Neurodegeneration	Neurologie_761	Höftberger Romana
FW761A0201	Inflammatory mechanisms of progression in Multiple Sclerosis	Neurologie_761	Zrzavy Tobias
FA728A1601	Cobas® Sense Calibration study, Study No. RD007069	Notfallmedizin_728	Gupta Sophie
FA737A1205	Travel Edgrant AKH - Konzepte in der Arthrosebehandlung	Orthopädie und Unfallchirurgie_739	Tögel Stefan
FA737A2004	Travel Edgrant AKH - Biomechanische Konzepte (Orthopädie)	Orthopädie und Unfallchirurgie_739	Benca Emir
FA681A0211	UNderstanding Lipid ImmunoMetabolism To trEat Disease	Pathobiochemie und Genetik_306	Weichhart Thomas
FW681A0303	Nuklearer Metabolismus: Enzym-Netzwerke und Epigenetik	Pathobiochemie und Genetik_306	Miller Anne Elisabeth
FW681A0401	Metabolic signaling in sarcoidosis	Pathobiochemie und Genetik_306	Weichhart Thomas
FA791A1164	A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD (-) Acute Myeloid Leukemia	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1165	A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma	Pathologie_791	Simonitsch-Klupp Ingrid

FA791A1166	A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1673	Neoadjuvant Treatment Optimization driven by ctDNA and Endocrine Responsiveness	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1674	A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1675	ABCSG 63 / ERIKA: Elacestrant and Ribociclib in Ki67-tested endocrine responsive breast cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1676	ABCSG 63 / ERIKA: Elacestrant and Ribociclib in Ki67-tested endocrine responsive breast cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer ABCSG 63 / ERIKA: Elacestrant and Ribociclib in Ki67-tested endocrine responsive breast cancer: An open-label, two-arm, randomized, phase II	Pathologie_791	Bago-Horvath Zsuzsanna

	study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer		
FA791A1677	A randomized phase II Study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling (The PONTIAC Study)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1678	Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A2117	A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell	Pathologie_791	Pammer Johannes
FA791A2806	A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH RESECTABLE STAGE III AND IV MELANOMA	Pathologie_791	Schiefer Ana-Iris
FA791A3423	AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer	Pathologie_791	Comperat Eva Maria

FA791A3424	A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)	Pathologie_791	Comperat Eva Maria
FA791A3425	CA244-0012: Randomized, Open-Label, Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy based treatment	Pathologie_791	Comperat Eva Maria
FA791A3426	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigators Choice in Participants with Chemotherapy naïve Metastatic Castration resistant Prostate Cancer	Pathologie_791	Comperat Eva Maria
FA791A3505	TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy as amended from time to time and incorporated herein by reference	Pathologie_791	Oberndorfer Felicitas
FA791A3506	A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation	Pathologie_791	Oberndorfer Felicitas
FA791A3902	CA061-1011: A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in	Pathologie_791	Kozakowski Nicolas

	Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants		
FA791A4105	A randomised, double blind, placebo controlled, multicentre, Phase III trial evaluating long term efficacy and safety of survodutide weekly injections in adult participants with non cirrhotic non alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) (F3) stage of liver fibrosis	Pathologie_791	Mozayani Behrang
FA791A4106	A Phase III double blind, randomised, placebo controlled trial to evaluate liver related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis	Pathologie_791	Mozayani Behrang
FA791A4107	A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma	Pathologie_791	Mozayani Behrang
FA791A4108	PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol) PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC) PROCEADE PanTumor: A Phase	Pathologie_791	Mozayani Behrang

	1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Non-Small Cell Lung Cancer (Substudy NSCLC) PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC)		
FA791A4109	A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	Pathologie_791	Mozayani Behrang
FA644A0805	Environmental Lassa Virus Investigation and Surveillance	Pathophysiologie, Infektiologie und Immunologie_370	Bergthaler Andreas
FW623A0501	Endosymbionts in Trichomonas vaginalis pathogenicity	Pathophysiologie, Infektiologie und Immunologie_370	Lesiak-Markowicz Iwona
FW623A0601	Mining and Dining- Prehistoric Miners Foodways. Microscopic and biomolecular dietary analysis of Bronze Age and Iron Age human paleofeces from the salt mines of Hallstatt	Pathophysiologie, Infektiologie und Immunologie_370	Walochnik Julia
FW648A0301	B cell and antibody repertoires in allergy therapy	Pathophysiologie, Infektiologie und Immunologie_370	Bohle Barbara
FA641A0607	DAVDP	Physiologie und Pharmakologie_350	Sitte Harald
FA641A1002	Heterologe Expression von Ionenkanälen in Zelllinien	Physiologie und Pharmakologie_350	Kudlacek Oliver
FA641A1502	Pharmakologische Protektion bei Kardioplegie	Physiologie und Pharmakologie_350	Zebedin-Brandl Eva Maria
FW641A0302	Harnessing A20 to Modulate Immunity in Lung Cancer	Physiologie und Pharmakologie_350	Moll Herwig

FW641A0801	Dynamics of T Cell Infiltration in EGFR-Driven Lung Cancer	Physiologie und Pharmakologie_350	Casanova Emilio
FW683A0201	SPARC: Stim and Plectin mediated Regulation of SERCA	Physiologie und Pharmakologie_350	König Xaver
FW683A0202	Cardiac Calcium in Cancer Cachexia	Physiologie und Pharmakologie_350	König Xaver
FA734A0301	A multicenter, prospective, randomized, placebo controlled, double blind, adaptive design study performed to evaluate the safety and the efficacy of EscharEx (EX-03 formulation) in debridement of Venous Leg Ulcers	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Radtke Christine
FW734A0201	Human Dorsal Root Ganglia Neuron Cultures from Body Donors	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Semmler Lorenz
FA763C0901	WE-MIND: Advancing Mental Health and Innovation in Western Balkans Higher Education Through Digital Transformation	Psychiatrie und Psychotherapie_763	Wagner-Menghin Michaela
UE76606002	Menopause: Transition or Turning Point? A Qualitative Pilot Study	Psychoanalyse und Psychotherapie_766	Leithner-Dziubas Katharina
FA638A0801	Compilation of database of individual patient data (IPD) of pediatric eumycetoma patients reported in the literature 1990-2025	Public Health_380	Erber Astrid Christine
FA646A0111	Priorisierung von Indikationen und Krankheitsbildern für indikationsbezogene Module der Integrierten Versorgung	Public Health_380	Rieder Anita
FA646A1801	Community engagement with older adults for good health and resilience in climate change adaptation	Public Health_380	Mair Lucia
FA647A0805	SHINE: Social and Health Impacts of climate change adaptation Efforts on long-term care	Public Health_380	Haluza Daniela
FA647A0806	Dynamische Klimaanalysen für resiliente und gesundheitswirksame Stadtentwicklung durch AI und Remote Sensing	Public Health_380	Haluza Daniela

FW646A0301	From Mat to Model - Stress, Inflammation, and Yoga	Public Health_380	Szaszko Bence
UE64606005	Kohortenstudie zu pflanzenbasierter Ernährung/Cohort on PLANT-based diets	Public Health_380	Wakolbinger Maria
FA771B1315	A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjogren's Disease (SjD), (80202135SJS3001 DAFFODIL)	Radiologie und Nuklearmedizin_771	Prosch Helmut
FA771B1905	A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B1906	A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B1907	A randomised, double-blind, placebo controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) and (F2) (F3) stage of liver fibrosis	Radiologie und Nuklearmedizin_771	Attenberger Ulrike
FA771B2001	Pan-European Breast Image Platform for Advanced AI-based Breast Cancer Screening	Radiologie und Nuklearmedizin_771	Clauser Paola

FA771D0537	A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH RESECTABLE STAGE III AND IV MELANOMA	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0538	DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0539	A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D1203	PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Non-Small Cell Lung Cancer (Substudy NSCLC)	Radiologie und Nuklearmedizin_771	Waneck Fredrik
FA771E1302	A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps	Radiologie und Nuklearmedizin_771	Czerny Christian
FA771E2101	BRaIn Disease monitoring through the life span powered by Artificial Intelligence	Radiologie und Nuklearmedizin_771	Licandro Roxane
FA771E2201	Hochauflösende 7T MRT zur Evaluation der Nervenablation mittels Diodenlaser am Kniegelenk prospektive Machbarkeits und Pilotstudie	Radiologie und Nuklearmedizin_771	König Felix Ragnar Merlin

FA771G0292	A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0293	PL2 - Intra- and Inter-Cellular Architecture in Health and Disease.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0294	An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0295	A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0296	AcTFIRST: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0297	Data analysis of cardiac amyloidosis	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0298	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigators Choice in Participants with Chemotherapy	Radiologie und Nuklearmedizin_771	Hacker Marcus

	naïve Metastatic Castration resistant Prostate Cancer		
FA771G0501	Durchführung von radioaktiven Markierungen, die Auswertung von SPECT/CT images und im weiteren die Durchführung von Tierstudien mit radioaktiv markiertem Fibrinogen (radiolabelled fibryga).	Radiologie und Nuklearmedizin_771	Wanek Thomas
FW771B0101	ImmunoMRI for assessment of tumor-associated macrophages	Radiologie und Nuklearmedizin_771	Mayerhöfer Marius
FA774A1701	Ultrasound-guided optimization of implant quality for intracavitary+interstitial cervix cancer brachytherapy with clinical, implant-related and dosimetric reference data from patients treated with the EMBRACEII protocol.	Radioonkologie_774	Eder-Nesvacil Nicole
FW774A0501	Carbon ion or photon irradiation for PDAC immunomodulation	Radioonkologie_774	Kerschbaum-Gruber Sylvia
FA733A0104	LifeLUNG	Thoraxchirurgie_733	Aigner Clemens
FA733A0105	Kryoanalgesie für postoperatives Schmerzmanagement nach Herzthoraxchirurgischen Operationen (Reduce - Register)	Thoraxchirurgie_733	Aigner Clemens
FA733A0106	Prolongierte Lungenpreservation bei 10°C vs. standard of care: eine multizentrische prospektive 'Non-inferiority' Studie	Thoraxchirurgie_733	Aigner Clemens
FA727A0623	An observational, Post-Authorisation Safety Study (PASS) to describe the safety and effectiveness of tabellecleucel in patients with Epstein-Barr Virus positive (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) in a real-world setting in Europe	Transfusionsmedizin und Zelltherapie_727	Worel Nina
FA727A0624	A Phase II, multipart, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus	Transfusionsmedizin und Zelltherapie_727	Worel Nina

	rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis.		
FA670B0501	The Impact of Vitamin D3 High Doses Supplementation on Soft Tissue Wound Healing after Mandibular Third Molar Removal	Universitätszahnklinik_670	Ulm Christian
FA670E0301	The Application of Upgraded Clear Aligners with an Occlusal Splint in orthodontics	Universitätszahnklinik_670	Rausch Marco Aoqi
FA670E0302	Development of a Cross-Age-Driven, DeepSeek-MoE Architecture-Based Multimodal Diagnostic System for Craniomandibular Dysfunction	Universitätszahnklinik_670	Rausch Marco Aoqi
FW670F0201	Personalized modeling of TMJ sexual dimorphism biomechanics	Universitätszahnklinik_670	Sagl Benedikt
UE67006003	Kooperationsvertrag DGKiZ (Weiterentwicklung Kinderzahnheilkunde)	Universitätszahnklinik_670	Bekes Katrin
FA670A0112	Kraftmessung an MAM Proben	Universitätszahnklinik_670	Schedle Andreas
FA743A0281	A phase III, open-label, multi-center, randomized study comparing AAA817 plus ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer	Urologie_743	Shariat Shahrokh
FA743A0282	A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)	Urologie_743	Shariat Shahrokh
FA743A0283	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigators Choice in Participants with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer	Urologie_743	Shariat Shahrokh

FA743A0284	A RANDOMIZED, OPEN-LABEL, PHASE 2/3 TRIAL OF IZALONTAMAB BRENGITECAN VERSUS PLATINUM-BASED CHEMOTHERAPY FOR METASTATIC UROTHELIAL CANCER IN PARTICIPANTS WITH DISEASE PROGRESSION ON OR AFTER AN IMMUNOTHERAPY-BASED TREATMENT	Urologie_743	Shariat Shahrokh
FA743A0701	Multimodal Strategies to Target Key Challenges in Bladder Cancer	Urologie_743	Englinger Bernhard

Markus Müller

Rektor